Mechanism targeting
Intervene in hallmarks of aging: cellular senescence, stem-cell exhaustion, and mitochondrial decline.
Track 2
Reverse biological aging
To sustain LEV, medicine must do more than slow decline. This track focuses on restoring lost biological function and rebuilding resilience.
What needs to improve
Biomarker rigor
Check biomarker changes against functional outcomes; a younger-looking marker alone does not establish rejuvenation.
Functional outcomes
Prioritize improvements in cognition, mobility, and organ function instead of proxy metrics alone.
Possible milestones
Research goals, not forecasts or a promised timeline.
Step 1
Rejuvenation effects become measurable
Interventions show repeatable biomarker and functional improvements in controlled settings.
Step 2
Protocols become combinatorial
Multi-pathway interventions outperform single-agent approaches across organ systems.
Step 3
Periodic restoration becomes routine
Clinical practice shifts toward scheduled biological restoration over passive decline management.
Main risks
- Weak endpoint standards across aging-intervention studies.
- Long safety horizons for interventions with systemic effects.
- Regulatory pathways not yet optimized for anti-aging indications.